Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alcon announces shares buy-back scheme

This article was originally published in Clinica

Executive Summary

Alcon is planning to repurchase up to one million shares from its investors by the end of 2008, the proceeds of which will be used to pay employee compensation plans. The ophthalmic products company, headquartered in Switzerland and the US, has around 70 million shares that are publicly traded, out of a total 300 million outstanding shares. The firm said the buy-back plan will not have a material effect on the interest percentages of its two major shareholders – Nestlé, which has a 52% stake, and Novartis, which has 25%.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT042520

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel